赛诺菲喜保宁怎么买？

(Vigabatrin tablets) is a drug that requires long-term use, because in 1997, foreign researchers first reported three cases of severe visual field damage in three patients after using vigabatrin. The emergence of this irreversible disabling damage was almost devastating to its market life, which made the drug face the problem of delisting.

However, at about the same time, researchers also found that Vigabatrin had an immediate effect on a type of infantile epilepsy for which there was no effective drug, and the efficiency was very high. In a small sample study, it showed significant efficacy. These findings have brought vigabatrin back from the cliff of delisting. The drug was first synthesized in 1974 and entered the clinical development stage for registration purposes in the 1970s. It was first approved for marketing in the UK in 1989. In the following years, the method was further promoted and applied. So, how to buy Sanofi Vigabatrin?

Up to now, France's Sanofi Vigabatrin has been launched in many countries and regions, but it has not yet been approved by the National Medical Products Administration (NMPA) to be officially launched in China. Therefore, patients who currently need this drug for treatment can only first purchase drugs overseas to meet their needs. According to Medical Companion Travel, a box of the Turkish version of Vigabatrin exported to France by Sanofi is priced at around $1,500, and the drug specification is 500 mg x 100 capsules per box. Domestic patients in need can contact some professional and formal overseas medical service organizations in China (such as Medical Companion Travel) to obtain purchase channels for the required drugs.

Sanofi is a leading global pharmaceutical and health company that focuses on patient needs and spreads health. Sanofi has more than 100,000 employees and its business covers many fields, including vaccines, prescription drugs, health pharmaceutical products and animal health products. The launch of Sanofi provides another new treatment option for many patients.

Recommended hot articles: /newsDetail/93759.html